Advancing Next-Generation Psychedelic Therapeutics through Selective 5‑HT2A Activation, Precision Aerosol Delivery, and Optimized 5‑MeO-DMT Treatment Paradigms. [PDF]
Renner AC, Kargbo RB.
europepmc +1 more source
Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors. [PDF]
Ekins TG +6 more
europepmc +1 more source
Retrosplenial cortex 5-HT2A receptors critically contribute to recognition memory processing. [PDF]
Ortega BA, Weisstaub NV, Katche C.
europepmc +1 more source
Novel Pyridine Derivatives as 5‑HT2A Agonists for Treating Psychiatric Disorders. [PDF]
Sabnis RW.
europepmc +2 more sources
Novel Ergolines as 5‑HT2A Agonists for Treating Mood Disorders. [PDF]
Sabnis RW.
europepmc +1 more source
Psychedelic 5-HT2A agonist increases spontaneous and evoked 5-Hz oscillations in visual and retrosplenial cortex. [PDF]
White CM +5 more
europepmc +1 more source
Psilocybin elicits a conserved glucocorticoid-responsive gene signature across five 5-HT2A receptor-rich brain regions in rat. [PDF]
Veysi A +4 more
europepmc +1 more source
Dibenzofuranylethylamines as 5‑HT2A/2C Receptor Agonists
Thirumal Yempala +5 more
doaj +1 more source
Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain Disorders. [PDF]
Sabnis RW.
europepmc +1 more source
Novel Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness, and CNS Disorders. [PDF]
Sabnis RW.
europepmc +1 more source

